Who Paid My Doc
Ngenla
Drug Endocrine Disease;Metabolic Disease
NDC 0069-0505-02
General payments
$432,718
Research payments
$245,654
Through program year 2025, $432,718 in general payments and $245,654 in research payments were reported against Ngenla (Endocrine Disease;Metabolic Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $234,888 | 1,019 |
| 2024 | General | $91,586 | 574 |
| 2024 | Research | $163,654 | 14 |
| 2023 | General | $106,244 | 309 |
| 2023 | Research | $82,000 | 1 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 25 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 38 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
1,902 general · 15 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.